Jessica E. Lisle
Woolloongabba, QLD, Australia
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
SUMOylation of EphB4 enhances its stability in prostate cancer.
Journal: British journal of cancer
Published: October 14, 2025
Erratum: Development of a gene edited next-generation hematopoietic cell transplant to enable acute myeloid leukemia treatment by solving off-tumor toxicity.
Journal: Molecular therapy. Methods & clinical development
Published: December 14, 2023
Development of a gene edited next-generation hematopoietic cell transplant to enable acute myeloid leukemia treatment by solving off-tumor toxicity.
Journal: Molecular therapy. Methods & clinical development
Published: June 23, 2023
Endothelial E-selectin inhibition improves acute myeloid leukaemia therapy by disrupting vascular niche-mediated chemoresistance.
Journal: Nature communications
Published: June 12, 2019
Inhibiting Eph kinase activity may not be "Eph"ective for cancer treatment.
Journal: Growth factors (Chur, Switzerland)
Published: November 22, 2014
Murine, but not human, ephrin-B2 can be efficiently cleaved by the serine protease kallikrein-4: implications for xenograft models of human prostate cancer.
Journal: Experimental cell research
Published: October 30, 2014
EphB4 localises to the nucleus of prostate cancer cells.
Journal: Experimental cell research
Published: October 03, 2014
Activation of membrane-bound proteins and receptor systems: a link between tissue kallikrein and the KLK-related peptidases.
Journal: Biological chemistry
Published: February 17, 2014
Eph receptors and their ligands: promising molecular biomarkers and therapeutic targets in prostate cancer.
Journal: Biochimica et biophysica acta
Published: November 20, 2012
Showing 1-11 of 11
Last Updated: 09/26/2026